MedAvail Holdings, Inc. reaffirmed financial guidance for the full year 2022. The company affirmed its previously issued guidance for full year 2022 revenue to be at least $42 million, representing growth of at least 90% over full year 2021 revenue. The company also affirms its guidance of 40 new net dispensing deployments for full year 2022.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0003 USD | -.--% | -.--% | -99.99% |
06/05 | Motion for Asset Sale Filed by MedAvail Holdings, Inc. | CI |
03/05 | Notice of Successful Bidder Filed by MedAvail Holdings, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
-99.99% | 484 | |
+16.34% | 88.8B | |
+10.43% | 68.32B | |
+16.25% | 37.54B | |
+20.57% | 34.19B | |
+3.35% | 27.45B | |
+6.92% | 26.25B | |
-1.14% | 26.21B | |
+17.43% | 25.26B | |
+3.06% | 22.44B |
- Stock Market
- Equities
- MYOS Stock
- News MedAvail Holdings, Inc.
- MedAvail Holdings, Inc. Reaffirms Financial Guidance for the Full Year 2022